CoFounders at the University of Pennsylvania discovered new mode of action for memory formation and re-consolidation that underlies the pathogenesis of psychiatric diseases: post-traumatic stress disorder (PTSD) and substance use disorders; Alzheimer’s disease; and dementia.

ACSS2 is necessary for the transcriptional induction of key neuronal genes and for the final stage of neuron differentiation.

EpiVario is developing a proprietary small molecule inhibitor of ACSS2 to modulate a novel epigenetic process that controls neuronal plasticity and is the key to long-term memory formation.

Studies show that knock out mice develop normally – ACSS2 is not an essential gene